Çѱ¹À¯¹æ¾ÏÇÐȸ Á¦17ȸ Ç׾Ͽä¹ý ½ÉÆ÷Áö¾ö : 2020-03-14±³À°ÀÏÀÚ : 2020-03-14
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ
±³À°ÁÖÁ¦ :
Á¦17ȸ Ç׾Ͽä¹ý ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : Á¤Áö¿µ
¿¬¶ôó : 02-3461-6060
À̸ÞÀÏ :
kbcs@kbcs.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¹æ»ç¼±Á¾¾çÇаú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 4 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Á¤È¸¿ø ÁØȸ¿ø ºñȸ¿ø »çÀüµî·Ï 3¸¸¿ø 3¸¸¿ø 5¸¸¿ø ÇöÀåµî·Ï 5¸¸¿ø 5¸¸¿ø 7¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-14 ¸¶¸®¾ÆȦ 09:10~09:30 Adjuvant endocrine therapy: Optimal duration, switching from tamoxifen to AI À±ÇöÁ¶(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 03-14 ¸¶¸®¾ÆȦ 09:30~09:50 CDK4/6 inhibitor in metastatic breast cancer ÀÌ°æÀº(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 03-14 ¸¶¸®¾ÆȦ 09:50~10:10 PI3K inhibitor and AKT inhibitor in metastatic breast cancer À̱ټ®(±¹¸³¾Ï¼¾ÅÍ)
Åä·Ð 03-14 ¸¶¸®¾ÆȦ 10:10~10:20 Discussion ()
ÈÞ½Ä 03-14 10:20~10:40 Coffee Break ()
±³À°½Ã°£ 03-14 ¸¶¸®¾ÆȦ 10:40~11:00 Optimal neoadjuvant/adjuvant systemic therapy ±èÇÑÁ¶(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 03-14 ¸¶¸®¾ÆȦ 11:00~11:20 Neoadjuvant/adjuvant therapy for small HER2 positive breast cancer ¾ÈÈñ°æ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 03-14 ¸¶¸®¾ÆȦ 11:20~11:40 Optimal systemic therapy for HR+HER2+ metastatic breast cancer À̼öÀÌ(µ¿¾ÆÀÇ´ë)
Åä·Ð 03-14 ¸¶¸®¾ÆȦ 11:40~11:50 Discussion ()
½Ä»ç 03-14 11:50~12:50 Lunch ()
±³À°½Ã°£ 03-14 ¸¶¸®¾ÆȦ 12:50~13:05 Optimal neoadjuvant/adjuvant systemic therapy ÀÌÁöÀº(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-14 ¸¶¸®¾ÆȦ 13:05~13:20 PARP Inhibitor in metastatic breast cancer ÀÓ¼®¾Æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-14 ¸¶¸®¾ÆȦ 13:20~13:35 Immune checkpoint inhibitor in metastatic breast cancer ¹ÚÀÎÇý(±¹¸³¾Ï¼¾ÅÍ)
Åä·Ð 03-14 ¸¶¸®¾ÆȦ 13:35~13:45 Discussion ()
ÈÞ½Ä 03-14 13:45~14:05 Coffee Break ()
±³À°½Ã°£ 03-14 ¸¶¸®¾ÆȦ 14:05~14:25 Role of surgery for lung metastasis in breast cancer patients À̱ٵ¿(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03-14 ¸¶¸®¾ÆȦ 14:25~14:45 Role Radiotherapy for oligometastasis in breast cancer patients (including radiosurgery) ¼ÛÁøÈ£(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-14 ¸¶¸®¾ÆȦ 14:45~15:05 Systemic therapy before/after local therapy ¹®¿ëÈ(Â÷ÀÇ°úÇдë)
Åä·Ð 03-14 ¸¶¸®¾ÆȦ 15:05~15:20 Discussion ()